immunitybio | Immunotherapy by ImmunityBio

Keyword	CPC	PCC	Volume	Score	Length of keyword
immunitybio	0.26	0.2	157	23	11

Keyword	CPC	PCC	Volume	Score
immunitybio	1.78	0.5	8467	49

Search Results related to immunitybio on Search Engine

Immunotherapy by ImmunityBio - Cancer Vaccine Research
immunitybio.com

https://immunitybio.com/

WEBImmunityBio is developing immunotherapy products and cell therapies for cancer that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. Learn More. Researching Ways to Prevent Cancer.

DA: 20 PA: 36 MOZ Rank: 98

Medical Studies & Immunotherapies - Advanced Clinical Research
immunitybio.com

https://immunitybio.com/about/

WEBDeveloping innovative, disease-altering therapies for those who need them the most. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious diseases. Learn more about our advanced clinical research and trials today.

DA: 4 PA: 40 MOZ Rank: 10

Fighting a war on two fronts: ImmunityBio targets cancer and
nature.com

https://www.nature.com/articles/d43747-020-00963-y

WEBImmunityBio, Inc. is a privately held immunotherapy company dedicated to effectively activating the immune system to seek out, attack and destroy cancer cells or viral particles and has one of...

DA: 90 PA: 66 MOZ Rank: 49

ImmunityBio Announces FDA Acceptance of Biologics
businesswire.com

https://www.businesswire.com/news/home/20220728006046/en/ImmunityBio-Announces-FDA-Acceptance-of-Biologics-License-Application-for-N-803-in-BCG-Unresponsive-Non-Muscle-Invasive-Bladder-Cancer-Carcinoma-In-Situ

WEBJul 28, 2022 · ImmunityBio, a leading clinical-stage immunotherapy company, filed the BLA based on positive results from a series of studies of the investigational treatment, including the ongoing QUILT 3.032...

DA: 42 PA: 6 MOZ Rank: 68

ImmunityBio, Inc. (IBRX) - Yahoo Finance
yahoo.com

https://finance.yahoo.com/quote/IBRX/

WEBImmunityBio, Inc. (IBRX) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.11 -0.95 (-15.68%) At close: 04:00PM EDT. 5.24 +0.13 (+2.54%) After hours: 07:58PM EDT.

DA: 100 PA: 67 MOZ Rank: 74

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and …
businesswire.com

https://www.businesswire.com/news/home/20231026155505/en/FDA-Accepts-ImmunityBio%E2%80%99s-BLA-Resubmission-as-Complete-and-Sets-New-PDUFA-Date/

WEBOct 26, 2023 · CULVER CITY, Calif.-- ( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has accepted...

DA: 40 PA: 3 MOZ Rank: 7

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and …
yahoo.com

https://finance.yahoo.com/news/fda-accepts-immunitybio-bla-resubmission-130000546.html

WEBOct 26, 2023 · CULVER CITY, Calif., October 26, 2023 -- ( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration...

DA: 37 PA: 72 MOZ Rank: 58

ImmunityBio Announces Completion of $470 Million Post-merger …
businesswire.com

https://www.businesswire.com/news/home/20211220005286/en/ImmunityBio-Announces-Completion-of-470-Million-Post-merger-Financing-to-Fund-Late-stage-Cancer-Clinical-Trials-Phase-3-of-COVID-T-Cell-Universal-Boost-Vaccine-Trial-and-Provides-Update-on-Bladder-Cancer-BLA-Filing

WEBDec 20, 2021 · CULVER CITY, Calif.-- ( BUSINESS WIRE )--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, has successfully raised an aggregate $470 million of equity and debt financing...

DA: 17 PA: 44 MOZ Rank: 72

ImmunityBio Announces Full Accrual of First Two Phases of
nasdaq.com

https://www.nasdaq.com/press-release/immunitybio-announces-full-accrual-of-first-two-phases-of-cancer-vaccine-trial-in

WEBFeb 21, 2024 · CULVER CITY, Calif. -- (BUSINESS WIRE)-- ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced that enrollment and initial follow-up has been completed for the...

DA: 96 PA: 9 MOZ Rank: 38

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells …
yahoo.com

https://finance.yahoo.com/news/first-data-immunitybio-memory-cytokine-140000492.html

WEBNov 7, 2023 · CULVER CITY, Calif., November 07, 2023 -- ( BUSINESS WIRE )--ImmunityBio, Inc. ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced new data showing that the company’s Memory...

DA: 38 PA: 4 MOZ Rank: 70